Cargando…

Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden

OBJECTIVES: In Sweden, breast cancer (BC) represents 30% of newly diagnosed cancers and is the most common cancer in women. For hormone-dependent BC, endocrine therapies varying in efficacy and price are available. The aim of this study is to assess the cost effectiveness of fulvestrant 500 mg as a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabale, Ugne, Ekman, Mattias, Thunström, Daniel, Telford, Claire, Livings, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711749/ https://www.ncbi.nlm.nih.gov/pubmed/29441507 http://dx.doi.org/10.1007/s41669-017-0031-6

Ejemplares similares

Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
por: Telford, Claire, et al.
Publicado: (2019)

Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial
por: Leo, Angelo Di, et al.
Publicado: (2013)

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer
por: Robertson, John FR, et al.
Publicado: (2013)

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant
por: Kümler, Iben, et al.
Publicado: (2016)

Brand versus generic dispensing trend for ciprofloxacin 500 mg, levofloxacin 500 mg, and moxifloxacin 400 mg (oral dosage forms) among pharmacies of Karachi, Pakistan
por: Zehra, Fatima, et al.
Publicado: (2017)

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
por: Ellis, Matthew J., et al.
Publicado: (2015)

Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China
por: Zhang, Qingyuan, et al.
Publicado: (2016)

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
por: Robertson, John F. R., et al.
Publicado: (2019)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial
por: Moscetti, Luca, et al.
Publicado: (2017)

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
por: García-Sáenz, José Á., et al.
Publicado: (2022)

Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China
por: Lei, Wen, et al.
Publicado: (2020)

Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospective case series
por: Huang, Jian, et al.
Publicado: (2020)

Revisiting Fulvestrant Dosing in Uncertain Economic Times
por: Patel, Amol, et al.
Publicado: (2021)

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
por: HOLE, STINE, et al.
Publicado: (2015)

Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis
por: Huang, Xing
Publicado: (2019)

Economic Burden of Cervical Cancer in Bulgaria
por: Lebanova, Hristina, et al.
Publicado: (2023)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li, Yi, et al.
Publicado: (2020)

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
por: Zhao, Yannan, et al.
Publicado: (2018)

Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
por: Palumbo, Raffaella, et al.
Publicado: (2019)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
por: Cameron, D A, et al.
Publicado: (2008)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial
por: Adelson, Kerin, et al.
Publicado: (2016)

Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005)

Aromatase inhibitors in male sex
por: Singh, Santosh Kumar
Publicado: (2013)

Aromatase inhibitors in the treatment of endometriosis
por: Słopień, Radosław, et al.
Publicado: (2016)

Molecular Docking of Aromatase Inhibitors
por: Suvannang, Naravut, et al.
Publicado: (2011)

Aromatase Inhibitors in Erectile Dysfunction
por: Singh, Santosh
Publicado: (2021)

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
por: Jones, Robert H, et al.
Publicado: (2020)

Aromatase inhibitors in advanced breast cancer: there are efficacy differences
por: Bhatnagar, A S
Publicado: (2005)

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

Fulvestrant and the sequential endocrine cascade for advanced breast cancer
por: Johnston, S
Publicado: (2004)

Oestradiol measurement during fulvestrant treatment for breast cancer
por: Owen, Laura J., et al.
Publicado: (2019)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

The effects of aromatase inhibitors on lipids and thrombosis
por: Bundred, N J
Publicado: (2005)

Safety of aromatase inhibitors in the adjuvant setting
por: Perez, Edith A.
Publicado: (2007)

Aromatase inhibitors--where are we now?
por: Miller, W. R.
Publicado: (1996)

Aromatase inhibitors in stimulated IVF cycles
por: Papanikolaou, Evangelos G, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_sqgm3jla5cqrfacl7sfctc06gp